World Journal of Clinical Oncology

Scope & Guideline

Fostering Collaboration in the Fight Against Cancer

Introduction

Immerse yourself in the scholarly insights of World Journal of Clinical Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2218-4333
PublisherBAISHIDENG PUBLISHING GROUP INC
Support Open AccessNo
Country-
TypeJournal
Convergefrom 2014 to 2018 (coverage discontinued in Scopus)
AbbreviationWORLD J CLIN ONCOL / World J. Clin. Oncol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address7041 Koll Center Parkway, Suite 160, PLEASANTON, CA 94566, UNITED STATES

Aims and Scopes

The World Journal of Clinical Oncology focuses on advancing the field of oncology through the dissemination of high-quality research that addresses various aspects of cancer diagnosis, treatment, and management. The journal emphasizes a multidisciplinary approach and aims to contribute significantly to the understanding and treatment of cancer through innovative research and clinical studies.
  1. Cancer Biomarkers and Prognostic Indicators:
    Research on cancer biomarkers is a core focus, investigating their role in predicting patient outcomes, treatment responses, and disease progression across various cancer types.
  2. Innovative Treatment Modalities:
    The journal publishes studies on new and emerging treatment strategies, including immunotherapy, targeted therapies, and combination therapies, focusing on their clinical applications and efficacy.
  3. Molecular and Genetic Insights:
    There is a significant emphasis on molecular and genetic research that explores the underlying mechanisms of cancer, including studies on genetic mutations, epigenetics, and cancer genomics.
  4. Patient-Centered Care and Quality of Life:
    The journal covers research aimed at improving patient care, addressing psychosocial aspects, quality of life, and challenges faced by cancer patients, particularly in diverse populations.
  5. Clinical Trials and Real-World Evidence:
    The journal prioritizes studies that report on clinical trials, real-world evidence, and systematic reviews that guide clinical practice and policy in oncology.
The World Journal of Clinical Oncology is witnessing a dynamic shift in research themes, with several emerging topics gaining traction in recent publications. These trends reflect the evolving landscape of oncology research and clinical practice.
  1. Immunotherapy and Novel Immune Targets:
    There is a marked increase in research focusing on immunotherapy, including the exploration of immune checkpoint inhibitors and novel immune targets, reflecting a significant paradigm shift in cancer treatment.
  2. Precision Medicine and Genomic Profiling:
    Emerging studies emphasize the role of precision medicine, particularly in tailoring treatments based on individual genetic profiles and tumor characteristics, highlighting advances in genomic technologies.
  3. Cancer Microenvironment and Metabolism:
    Research exploring the tumor microenvironment and metabolic pathways in cancer is gaining attention, as understanding these factors is crucial for developing effective therapeutic strategies.
  4. Technological Innovations in Cancer Detection:
    There is a growing trend in the utilization of advanced technologies, such as machine learning and bioinformatics, to enhance cancer detection, diagnosis, and monitoring, indicating a shift towards more data-driven approaches.
  5. Psychosocial Factors in Cancer Care:
    An increasing number of studies are addressing the psychosocial aspects of cancer care, including the impact of mental health on treatment outcomes and the importance of supportive care interventions.

Declining or Waning

While the journal continues to thrive in various areas, certain themes appear to be declining in prominence based on recent publications. This may indicate shifts in research focus or advancements in the understanding of specific topics.
  1. Traditional Chemotherapy Approaches:
    There seems to be a waning interest in traditional chemotherapy protocols as the focus shifts towards personalized medicine and targeted therapies, which are perceived as more effective and less toxic.
  2. Basic Science without Clinical Implications:
    Research that does not directly translate into clinical application appears to be less frequently published, reflecting a trend towards studies that emphasize practical outcomes and patient impact.
  3. General Cancer Epidemiology Studies:
    While epidemiological studies remain important, there is a noticeable decline in publications focusing on broad epidemiological data without specific interventions or outcomes, as the journal seems to prioritize more targeted research.

Similar Journals

World Journal of Gastrointestinal Oncology

Fostering innovation in the fight against gastrointestinal disorders and cancer.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Nature Reviews Clinical Oncology

Unlocking Innovations in Oncology Research
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Oncology Reviews

Pioneering Knowledge in Oncology and Beyond
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Bladder Cancer

Connecting clinicians and scholars in the fight against bladder cancer.
Publisher: IOS PRESSISSN: 2352-3727Frequency: 4 issues/year

Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

Journal of the National Comprehensive Cancer Network

Advancing Oncology: Pioneering Research for Better Patient Outcomes
Publisher: HARBORSIDE PRESSISSN: 1540-1405Frequency: 15 issues/year

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

Frontiers in Oncology

Pioneering new frontiers in cancer knowledge and treatment.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Colorectal Cancer

Elevating Research to Improve Patient Outcomes
Publisher: TAYLOR & FRANCIS LTDISSN: 1758-194XFrequency: 4 issues/year

Colorectal Cancer is an esteemed academic journal published by Taylor & Francis Ltd, focusing on all aspects of colorectal cancer research, diagnosis, treatment, and prevention. With an ISSN of 1758-194X and an E-ISSN of 1758-1958, this journal serves as a critical platform for publishing innovative studies, clinical trials, and meta-analyses to advance the understanding of colorectal cancer. Though not yet categorized under open access, it provides valuable insights and is committed to enhancing the visibility of research contributions within the field. The journal aims to foster collaboration and communication among researchers, clinicians, and students dedicated to improving patient outcomes and exploring novel therapeutic strategies. With its rigorous editorial standards, Colorectal Cancer plays a pivotal role in shaping future research and clinical practices, making it indispensable for professionals in oncology, gastroenterology, and related fields.

JOURNAL OF CLINICAL ONCOLOGY

Leading the charge in oncological excellence and discovery.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

JTO Clinical and Research Reports

Pioneering Excellence in Clinical and Research Insights
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Targeted Oncology

Pioneering the path to targeted cancer therapies.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.